Login

|

Register

  • Home

    • Amazon FBA Support

      Amazon handed prep work back to sellers, and the consequences of getting it wrong land on you rather than on them. A carton that arrives wrong gets refused, refused stock sits somewhere earning nothing, and a launch date moves.

      Amazon FBM Support

      FBM keeps the things worth keeping. Your packaging, customer data & margin. It also puts Amazon’s performance metrics directly on your dispatch times, which is a comfortable trade at home and a much harder one from four thousand miles away.

      Direct-to-Consumer Fulfilment

      On a marketplace, a slow delivery is the marketplace’s fault. On your own store it is yours. The box that arrives, the day it arrives and how easy it is to send back are all part of what someone bought, and they decide whether a first order becomes a second one.

      Returns, Reworks & Recycling

      Treated as a cost, a return is written off twice, once on the refund and again on the unit. Treated as inventory, a lot of it goes back on sale. What decides which of those happens is how quickly the unit gets looked at and how far it had to travel to be looked at.

      Warehouse Location

      Stock held inside the market it sells into arrives as a domestic delivery. No customs event on the order, and nothing for your customer to settle before the courier hands the parcel over. Ours sits in the UK, the Netherlands and the US, which covers...

  • Contact Us

Expandly Blog

EFSA Clears β-NMN – What the Positive Safety Opinion Means for Supplement Brands

EFSA issued a positive safety opinion on EffePharm’s β-Nicotinamide Mononucleotide in Q2 2026, clearing the novel food pathway for EU authorisation and putting NMN-selling brands on notice.

In This Article

01 What EFSA's positive opinion actually means
02 NMN's novel food status in the EU
03 Proprietary data protection and other suppliers
04 Compliance risk for brands already selling NMN in EU
05 Next steps before EU authorisation is published

Key Takeaways

► EFSA's positive opinion opens EU authorisation pathway for NMN
► Full EC authorisation still pending Official Journal publication
► NMN remains a novel food in EU — selling without authorisation is a breach
► Take legal advice on current EU exposure before authorisation is confirmed

EFSA published a positive safety opinion on EffePharm's β-Nicotinamide Mononucleotide (β-NMN) in Q2 2026, clearing the novel food authorisation pathway for EU markets. Full authorisation is pending publication in the Official Journal of the European Union. For supplement brands selling NMN in the US and UK, this is the most significant regulatory development in EU novel food for longevity ingredients in years — and it carries a compliance implication for those already selling into Europe without authorisation.

β-NMN Positive EFSA safety opinion confirmed Q2 2026, clearing the EU novel food authorisation pathway. Full EC authorisation pending Official Journal publication. Source: EFSA, Q2 2026.

β-NMN is classified as a novel food in the EU, meaning it cannot be legally sold as a supplement or food ingredient without a specific authorisation granted through the European Commission. EFSA's positive safety opinion is the critical preceding step to that authorisation — it confirms the ingredient is safe at the proposed use levels. The opinion was based on EffePharm's proprietary application. While the authorisation pathway is now open, the final EC regulation specifying authorised uses, maximum daily doses and labelling conditions is still pending Official Journal publication.

Proprietary data protection is relevant here. EffePharm's application was submitted under the novel food regulation, which grants data exclusivity for a defined period. Other NMN manufacturers seeking to sell in the EU may need to submit separate applications or demonstrate that they are not relying on EffePharm's proprietary safety data. The authorisation, once published, will specify the approved manufacturer or source. Brands using NMN from different suppliers should take specific legal advice on whether they will need their own application or can trade under any existing general permission.

The implication for US brands currently selling NMN products into EU markets is direct: selling a novel food without authorisation in the EU is a compliance breach, regardless of the product's legal status in the US or UK. EFSA's positive opinion does not retroactively legitimise historic EU sales. It opens the pathway for compliant EU market entry once the EC regulation is published. Brands with EU exposure should take legal advice on their current position while the authorisation process completes.

  • EFSA positive safety opinion on β-NMN confirmed Q2 2026 — full EC authorisation pending Official Journal publication
  • Proprietary data protection applies to EffePharm's application — other manufacturers may need separate applications
  • NMN remains a novel food in EU until formal authorisation is published — no retroactive permission for historic EU sales
  • US brands selling NMN into EU without authorisation should take legal advice on current compliance exposure

Expandly's compliance onboarding includes novel food status checks as part of the pre-launch product review, so supplement brands understand their EU authorisation position before any stock crosses the border.

Expandly helps US ecommerce brands expand into Europe — compliance, marketplaces and fulfilment, all handled. We’ve supported 2,000+ brands make the move.

Find out more
  • VAT registration handled across UK, Germany, Netherlands and all EU markets
  • EPR compliance managed from day one — packaging, WEEE, batteries and beyond
  • Product label review and Responsible Person service for EU and UK market entry

The bigger picture

EU Novel Food Authorisation affects NMN brands entering Europe now.

EFSA's positive safety opinion on β-NMN is a regulatory milestone for supplement brands with longevity and NAD+ products — but it does not mean NMN is now freely saleable in the EU. Novel food authorisation in the EU requires a formal EC regulation, and brands selling NMN without that authorisation carry real compliance risk, regardless of US or UK legal status. Expandly's compliance onboarding for supplement brands includes a pre-launch novel food check against the EU Novel Food Catalogue as a standard step. That check identifies ingredient authorisation status before products enter the EU, so brands enter with a clear legal position rather than discovering a compliance gap after their first shipment.

  • EU Novel Food Regulation (EU) 2015/2283 governs NMN and other novel ingredients — authorisation is required before sale
  • Expandly's compliance onboarding includes novel food status review against the EU Novel Food Catalogue for supplement brands
  • Responsible Person designation for EU supplement brands is a separate requirement managed as part of Expandly's market entry setup

EU NMN Market Demand

NMN is among the fastest-growing longevity supplement categories in US and UK retail. EFSA's positive safety opinion signals the EU market is opening. Once authorisation is published, brands with compliant formulations and EU setup will move first.

Q2 2026

EFSA positive safety opinion published — EU authorisation pathway now open

EU Supplement Compliance Requirement

Directive 2002/46/EC requires a Responsible Person designation for food supplements in each EU market. Novel food ingredients require separate EC authorisation on top of standard supplement compliance. Both must be in place before any product reaches an EU consumer.

27

EU member states requiring Responsible Person designation under Directive 2002/46/EC

EU Responsible Person, Included

Cosmetics, supplements and electronics sold in the EU require a designated Responsible Person. Expandly provides this designation as part of your compliance setup, with no separate service or third party required.

2,000+

brands expanded with Expandly

If this sounds like your world,
let's talk.

Expandly helps US ecommerce brands expand into Europe — compliance, marketplaces and fulfilment, all handled.

Self-Serve

  • £1,150/month
  • Platform-led with email support
  • Best for: $1M–$5M brands

Guided

  • £3,000/month
  • Dedicated Account Manager
  • Best for: $5M–$20M brands

VIP

  • £5,000/month
  • Dedicated VIP Consultant
  • Best for: $20M–$50M+ brands
See full pricing and what's included